Plasma levels of oxybutynine chloride in children.
Anticholinergic adverse-effects in children treated with conventional doses of oxybutynine led us to measure plasma oxybutynine levels in children. 18 children, aged 5 to 13 y, who required treatment with oxybutynine chloride for daytime incontinence were studied. Plasma concentrations were measured on the fifth day of a course of treatment in which the dose was adapted to the child's body weight; the dose was given twice daily at 12-hour intervals. In 10 children aged between 5 and 8 y, the mean dose was 0.1 mg.kg-1. In 8 children aged between 10 and 13 years, the mean dose was 0.15 mg.kg-1. The highest concentration was usually found between 1 and 2 h after administration. The subsequent fall in concentration was rapid and after 6 h oxybutynine was no longer measurable in 14 of the children. The concentrations found were not different from those seen in adults given equivalent doses. The results show that plasma concentrations in children were not very different from those observed in adults if the dose were adapted to the body weight of the children. No special differences in paediatric use were revealed that might explain the particular adverse-effects. The results of the study argue against the dosage regimen proposed before these adverse events were detected. They strongly favour a dose adapted to the body weight of the child, with a 12-hour interval between doses.
Autret
E
E
Department of Clinical Pharmacology, University Hospital of Tours, France.
Jonville
A P
AP
Dutertre
J P
JP
Bertiere
M C
MC
Robert
M
M
Averous
M
M
Couet
W
W
D000293:Adolescent; D000375:Aging / Q000378:metabolism; D001835:Body Weight; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D010276:Parasympatholytics / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D014549:Urinary Incontinence / Q000097:blood / Q000188:drug therapy; D014555:Urination Disorders / Q000097:blood / Q000188:drug therapy
D008333:Mandelic Acids; D010276:Parasympatholytics; C005419:oxybutynin